PHOENIX BIOTECH ACQUISITION CORP.
🇺🇸United States
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Phase 1
Recruiting
- Conditions
- AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CERo Therapeutics Holdings, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06834282
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath